Vertex says telaprevir may cut down HCV treatment time

08/11/2010 | Google

Some hepatitis C patients who took drug candidate telaprevir were able to finish treatment sooner than with standard therapy, according to Vertex Pharmaceuticals. The company said patients in the clinical trial who responded quickly to telaprevir had better results after 24 weeks of therapy compared with 48 weeks.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC